He studied Business Administration and Management at ESADE. He began working in marketing and soon his career moved into international business development. For a period, he specialized in the market in Africa, where he headed up sales for a Catalan multinational corporation, from Barcelona. In 2016, he co-founded IOMED and he is now CEO and Business Developer for the company.
He has a degree in Business from IQS and has worked in marketing departments at large multinational corporations. He specialized in digital marketing in the sports sector until he decided to take the leap as an entrepreneur in 2015, leaving it all to focus solely on his company: WeFitter.
With a degree in Mechanical Engineering and Industrial Organization and a Master in Business Innovation, Marc Rafat worked in the automotive and industrial machinery sector for 15 years. When his wife died of cancer, though, he left it all to move into the healthcare sector. After doing the d·HEALTH Barcelona fellowship, promoted by Biocat, he founded his own business, HealthQuay, through which he aspires to help other oncology patients.
She studied Psychology and a Master in Health Research at the Autonomous University of Barcelona (UAB). After some years as a researcher at the Hospital del Mar Research Institute, in 2008 she co-founded HumanITcare, a platform to monitor patients’ healthcare information, where she is currently CEO.
She studied Physics at the University of Barcelona and got her PhD in this field in 2003. Throughout her career, however, she has focused on electronic micro devices and, in recent years, micro electrochemical power sources. She is currently an ICREA professor at the Barcelona Microelectronics Institute.
PhD in Neurogenetics and Neuroscience from the University of Barcelona and Baylor College of Medicine in Houston. He did his postdoc in the US and, in 2017, moved to the Institute of Research Germans Trias I Pujol (IGTP), where he heads up the Neurogenetics Research Unit. After extensive experience as a project coordinator, peer reviewer for science journals and business adviser in Spain and abroad, in 2018 he co-founded the spin-off Biointaxis to develop treatments for Friedreich Ataxia and other minority neurological diseases.